Tempus AI Inc. stocks have been trading up by 10.7 percent amid heightened optimism over its healthcare-focused AI innovations.
Key Takeaways
- Multi‑year Bristol Myers Squibb agreement locks in oncology data licensing for Tempus AI through 2031 and showcases the Lens AI platform.
- A new $55M, five‑year Pathos neurology data deal shows Tempus AI leveraging its oncology backbone into a broader disease footprint.
- Bristol Myers Squibb now becomes one of Tempus AI’s largest licensors of de‑identified oncology data, deepening that relationship.
- An expanded Moderna and Merck collaboration embeds Tempus AI in individualized cancer vaccine development using KEYTRUDA.
- TEM traded about 2.9% lower pre‑market when the Moderna–Merck expansion hit, despite the clear strategic upside for Tempus AI.
Live Update At 11:32:08 EST: On Monday, November 02, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 10.7%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TEM has been on a sharp upswing. Over the last several sessions, Tempus AI stock climbed from the mid‑$60s to close near $79.89, showing strong momentum and aggressive dip buying. That’s a big move in a short time frame, which always gets short‑term traders paying attention.
Intraday, TEM has traded like a classic momentum name. The 5‑minute chart shows an early shakeout down to about $70.30, followed by a steady grind higher into the high‑$70s and low‑$80s. For day traders, that intraday reversal signals active support and high liquidity.
More Breaking News
- IOVA Stock Collapses As Traders Flee Biotech High‑Flier
- REGN Stock Climbs As Libtayo Data And Targets Rise
- SOFI Stock Slips As Analyst Cuts Price Target To $15
- Regeneron Stock Jumps As Libtayo Data Fuels Bullish Targets
Under the hood, Tempus AI is still a growth‑stage story. Revenue runs around $1.27B with a fat 73.5% gross margin, but operating and net margins are negative. TEM posts negative returns on equity and assets, while trading at a rich price‑to‑sales multiple near 9 and a price‑to‑book near 29. The balance sheet, though, shows strength: a current ratio around 3.3 and solid cash of roughly $600M. For traders, that mix screams “high‑growth, not yet fully scaled,” backed by enough liquidity to keep funding expansion.
Why Traders Are Watching Tempus AI Now
Tempus AI is stacking real, contracted dollars behind its story, and that is what many growth names lack. The headline win for TEM is the multi‑year deal with Bristol Myers Squibb. BMS will license Tempus AI’s multimodal, de‑identified oncology data through 2031 and tap its GPU‑enabled Lens AI platform to speed up oncology drug discovery and clinical development. For traders, that 2031 end date matters. It turns the TEM pipeline narrative into visible, long‑dated data revenue.
Just as important, Bristol Myers Squibb becomes one of Tempus AI’s largest oncology data licensors. That elevates TEM from “promising AI startup” into core infrastructure for a top‑tier pharma player. When a company the size of BMS builds around your data and AI stack, it is a clear validation signal that momentum and quant traders tend to respect.
Tempus AI is also stepping beyond cancer. A five‑year, $55M agreement with Pathos brings a large curated, de‑identified longitudinal dataset in neurological conditions. TEM is effectively re‑using its oncology infrastructure to build neurology datasets, while locking in a defined revenue stream from Pathos. The three‑party collaboration among Tempus AI, Pathos, and Bristol Myers Squibb hints at a broader network effect: TEM sits in the middle, monetizing data across multiple partners and therapeutic areas.
Layer on top the expanded multi‑year collaboration with Moderna and Merck around intismeran autogene (V940/mRNA‑4157), an individualized neoantigen cancer therapy being evaluated with KEYTRUDA. Tempus AI will manage tumor and blood sample logistics and run next‑generation sequencing (NGS) used in the design and manufacturing workflow. Even though TEM traded about 2.9% lower pre‑market on that news day, the strategic read is clear: big pharma is wiring TEM’s platform into some of the most cutting‑edge oncology programs in the market.
Conclusion
For active traders, TEM sits at the crossroads of AI, data, and precision medicine — all themes that attract speculative capital. The recent Bristol Myers Squibb deal extends Tempus AI’s revenue visibility deep into the next decade and locks BMS in as one of its largest licensors. The Pathos agreement adds $55M over five years, opens a neurology revenue lane, and reinforces Tempus AI’s role as the data hub in a three‑way pharma–tech network.
At the same time, the expanded Moderna and Merck collaboration shows how deeply Tempus AI technology is embedded in individualized cancer vaccine development. If intismeran autogene moves toward commercialization, TEM stands to benefit from the NGS and logistics work that underpins the program, even though timing and outcomes stay uncertain. Price action already reflects this potential: strong uptrends, fast intraday reversals, and clear demand for TEM shares on dips.
For traders who study charts and news flow, the setup is textbook growth plus catalysts, paired with real execution risk and rich valuation. As Tim Sykes often says, “The market doesn’t reward what’s possible, it rewards what’s proven and timely.” And as Tim Bohen, lead trainer with StocksToTrade says, “If you’re still guessing at the end of your analysis, it’s probably not a trade worth taking.” Tempus AI is now in the phase of proving that its monster data deals and pharma collaborations can translate into durable, scalable cash flows — and that is exactly why disciplined, research‑driven traders keep TEM on their radar.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.